SoftOx Solutions

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 15:45:00 19/05/2026 BST			5-day change	1st Jan Change
0.1304 ^NOK	+4.65%		+11.45%	+48.52%

04-13	Softox Solutions Issues Shares to Long State Investments Under Committed Financing Facility Deal	MT
04-12	SoftOx Solutions AS announced that it expects to receive NOK 7.2 million in funding from Long State Investments Limited	CI

SoftOx Solutions Issues 60 Million Shares to Long State Investments

Published on 11/28/2025 at 04:02 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about SoftOx Solutions

04-13	Softox Solutions Issues Shares to Long State Investments Under Committed Financing Facility Deal	MT
04-12	SoftOx Solutions AS announced that it expects to receive NOK 7.2 million in funding from Long State Investments Limited	CI
03-25	SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-03	Softox Solutions as Announces First Subject Dosed in Combined Phase 2A Dose-Escalation and Proof-Of-Concept Trial	CI
02-25	Health Products Regulatory Authority Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy	CI
12-29	Danish Medicines Agency Approves Phase 2A Trial for Softox Inhalation Solution	CI
12-29	SoftOx Solutions Lands Approval for Inhalation Therapy's Mid-stage Study in Denmark	MT
11-28	SoftOx Solutions Issues 60 Million Shares to Long State Investments	MT
11-28	Softox Solutions resolved on private placement	RE
11-26	SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Softox Solutions as Announces Gmp Drug Substance Successfully Manufactured - Key Milestone for Cf and Edf Clinical Programs	CI
16/10/25	SoftOx Solutions Unit Submits Clinical Trial Application for Inhalation Therapy	MT
16/10/25	SoftOx Defense Solutions AS Submits Phase 1 Clinical Trial Application Under the European Defence Fund Program	CI
06/10/25	SoftOx Solutions AS announced that it expects to receive NOK 1.149 million in funding from Long State Investments Limited	CI
01/10/25	SoftOx Solutions AS Announces Clinical Trial Application for Dose Escalation / Cystic Fibrosis Phase 2a	CI

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâ€™s product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Employees

Sector

Biotechnology & Medical Research

Calendar

05-27 - Earnings release - Annual 2025

More about the company